This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Condition	Treatment or Intervention	Phase
Prostate Cancer	Drug: AMG 162	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Male

Criteria

Other criteria also apply

For additional information regarding investigative sites for this trial, contact the Amgen Call Center at:      866-572-6436 

Alabama
      Research Site, Birmingham,  Alabama,  United States; Recruiting
Arizona
      Research Site, Tucson,  Arizona,  United States; Recruiting
California
      Research Site, Anaheim,  California,  United States; Recruiting
      Research Site, Greenbrae,  California,  United States; Recruiting
      Research Site, Long Beach,  California,  United States; Recruiting
      Research Site, Oakland,  California,  United States; Recruiting
      Research Site, San Bernardino,  California,  United States; Recruiting
      Research Site, San Diego,  California,  United States; Recruiting
      Research Site, Fresno,  California,  United States; Recruiting
      Research Site, Los Angeles,  California,  United States; Recruiting
Florida
      Research Site, Miami,  Florida,  United States; Recruiting
      Research Site, Spring Hill,  Florida,  United States; Recruiting
Illinois
      Research Site, Chicago,  Illinois,  United States; Recruiting
      Research Site, Oak Brook,  Illinois,  United States; Recruiting
Indiana
      Research Site, Muncie,  Indiana,  United States; Recruiting
Minnesota
      Research Site, St. Cloud,  Minnesota,  United States; Recruiting
Nebraska
      Research Site, Omaha,  Nebraska,  United States; Recruiting
New Jersey
      Research Site, Albany,  New Jersey,  United States; Recruiting
      Research Site, Berlin,  New Jersey,  United States; Recruiting
      Research Site, Lawrenceville,  New Jersey,  United States; Recruiting
      Research Site, West Orange,  New Jersey,  United States; Recruiting
      Research Site, Garden City,  New Jersey,  United States; Recruiting
      Research Site, Marlton,  New Jersey,  United States; Recruiting
New York
      Research Site, Mineola,  New York,  United States; Recruiting
      Research Site, Staten Island,  New York,  United States; Recruiting
      Research Site, Syracuse,  New York,  United States; Recruiting
North Carolina
      Research Site, Charlotte,  North Carolina,  United States; Recruiting
Oklahoma
      Research Site, Oklahoma City,  Oklahoma,  United States; Recruiting
Oregon
      Research Site, Eugene,  Oregon,  United States; Recruiting
South Carolina
      Research Site, Greenville,  South Carolina,  United States; Recruiting
      Research Site, Myrtle Beach,  South Carolina,  United States; Recruiting
Tennessee
      Research Site, Nashville,  Tennessee,  United States; Recruiting
Texas
      Research Site, Carrollton,  Texas,  United States; Recruiting
      Research Site, Corsicana,  Texas,  United States; Recruiting
      Research Site, Dallas,  Texas,  United States; Recruiting
      Research Site, Ft. Worth,  Texas,  United States; Recruiting
      Research Site, Sugar Land,  Texas,  United States; Recruiting
Virginia
      Research Site, Richmond,  Virginia,  United States; Recruiting
Washington
      Research Site, Seattle,  Washington,  United States; Recruiting

Study ID Numbers:  20040138
Record last reviewed:  September 2004
Record first received:  August 9, 2004
ClinicalTrials.gov Identifier:  NCT00089674
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-09